

Francesco Mario Boccardo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4977375/francesco-mario-boccardo-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

218
papers

16,759
citations

38
h-index

128
g-index

232
ext. papers

18,866
ext. citations

5.4
avg, IF

7.24
L-index

#	Paper	IF	Citations
218	Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. <i>Lancet, The</i> , 2005 , 365, 1687-717	4.0	5877
217	Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. <i>Lancet, The</i> , 2005 , 366, 2087-106	4.0	3823
216	Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. <i>Lancet, The</i> , 2015 , 386, 1341-1352	4.0	748
215	Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. <i>Journal of Clinical Oncology</i> , 2010 , 28, 509-18	2.2	615
214	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology, The</i> , 2018 , 19, 27-39 ¹⁻⁷	4.13	413
213	Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5138-47	2.2	375
212	Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. <i>Journal of Clinical Oncology</i> , 2001 , 19, 343-53	2.2	348
211	Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. <i>Lancet Oncology, The</i> , 2006 , 7, 991-6	21.7	198
210	Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. <i>Annals of Oncology</i> , 2006 , 17 Suppl 7, vii10-4	10.3	153
209	Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2718-27	2.2	152
208	Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. <i>Annals of Oncology</i> , 2012 , 23, 695-700	10.3	138
207	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019 , 393, 1440-1452	4.0	137
206	Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2027-38	2.2	133
205	Etiology of nonimmune hydrops fetalis: a systematic review. <i>American Journal of Medical Genetics, Part A</i> , 2009 , 149A, 844-51	2.5	125
204	Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 808-15	2.2	105
203	Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. <i>Journal of Urology</i> , 1991 , 146, 377-81	2.5	100
202	Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. <i>Lancet, The</i> , 1996 , 347, 1066-71	4.0	99

201	HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. <i>Oncology</i> , 2005 , 68, 154-61	3.6	96
200	A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group. <i>Journal of Urology</i> , 1991 , 146, 1321-6	2.5	96
199	Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. <i>Journal of Clinical Oncology</i> , 1990 , 8, 1310-20	2.2	83
198	High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. <i>Journal of Clinical Oncology</i> , 1996 , 14, 351-6	2.2	79
197	Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group. <i>European Journal of Cancer</i> , 1993 , 29A, 1088-93	7.5	78
196	Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. <i>Journal of Immunology</i> , 2011 , 186, 6044-55	5.3	77
195	Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. <i>Journal of Clinical Oncology</i> , 2001 , 19, 4209-15	2.2	75
194	Congenital pulmonary lymphangiectasia. <i>Orphanet Journal of Rare Diseases</i> , 2006 , 1, 43	4.2	58
193	Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. <i>European Journal of Cancer</i> , 2004 , 40, 84-9	7.5	56
192	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. <i>European Journal of Cancer</i> , 2013 , 49, 2134-42	7.5	55
191	Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. <i>Gynecologic Oncology</i> , 2004 , 93, 345-52	4.9	53
190	Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial. <i>European Journal of Cancer</i> , 2002 , 38, 473-80	7.5	52
189	Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. <i>British Journal of Cancer</i> , 2009 , 100, 1608-16	8.7	49
188	Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group. <i>Urology</i> , 1998 , 52, 72-81	1.6	49
187	A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 1041-52	7.4	43
186	Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. <i>Journal of Clinical Oncology</i> , 1994 , 12, 7-13	2.2	42
185	Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study. <i>Cancer</i> , 1992 , 69, 648-50	6.4	41
184	Endocrine Effects of Tamoxifen in Postmenopausal Breast Cancer Patients. <i>Tumori</i> , 1984 , 70, 61-68	1.7	41

183	CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials. <i>Breast Cancer Research and Treatment</i> , 2018 , 172, 9-21	4.4	38
182	Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014 , 10, 975-83	3.6	38
181	Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 661-8	4.4	38
180	Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. <i>European Urology</i> , 2002 , 42, 481-90	10.2	36
179	Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. <i>Cancers</i> , 2019 , 11,	6.6	35
178	Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine. <i>Current Drug Targets</i> , 2015 , 16, 47-59	3	34
177	Hennekam syndrome presenting as nonimmune hydrops fetalis, congenital chylothorax, and congenital pulmonary lymphangiectasia 2003 , 120A, 92-6		34
176	Alternating chemo-radiotherapy in bladder cancer: a conservative approach. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995 , 33, 173-8	4	34
175	Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1546-62	8.8	32
174	Periostin: a novel prognostic and therapeutic target for genitourinary cancer?. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 301-11	3.3	32
173	Carboplatin in advanced hormone refractory prostatic cancer patients. <i>European Journal of Cancer</i> , 1993 , 29A, 2094-6	7.5	32
172	Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death. <i>BMC Cancer</i> , 2012 , 12, 625	4.8	31
171	Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. <i>Targeted Oncology</i> , 2015 , 10, 393-404	5	30
170	Role of microRNAs in malignant mesothelioma. <i>Cellular and Molecular Life Sciences</i> , 2014 , 71, 2865-78	10.3	30
169	An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients. <i>European Urology</i> , 2010 , 57, 238-45	10.2	30
168	Enterolactone as a risk factor for breast cancer: a review of the published evidence. <i>Clinica Chimica Acta</i> , 2006 , 365, 58-67	6.2	29
167	Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer. <i>Journal of Cellular Biochemistry</i> , 2000 , 79, 471-485	4.7	29
166	Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest. <i>Gynecologic Oncology</i> , 1997 , 65, 499-505	4.9	28

165	Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities. <i>JCO Oncology Practice</i> , 2020 , 16, e1304-e1314	2.3	26
164	Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial. <i>European Journal of Cancer</i> , 2013 , 49, 1546-54	7.5	26
163	Randomized cooperative study of perioperative chemotherapy in breast cancer. <i>Journal of Clinical Oncology</i> , 1995 , 13, 2712-21	2.2	26
162	Multicenter randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. International Prostate Cancer Study Group. <i>Cancer</i> , 1993 , 72, 3878-9	6.4	26
161	Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERTility (PREFER) study. <i>Breast</i> , 2018 , 41, 51-56	3.6	26
160	Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. <i>Breast Cancer Research and Treatment</i> , 2016 , 157, 587-96	4.4	25
159	Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1529-39	9.7	25
158	Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials. <i>Cancer</i> , 2007 , 109, 1060-7	6.4	25
157	Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU). <i>Journal of Clinical Oncology</i> , 2008 , 26, 1094-1094	2.2	23
156	Prognostic Value of Preoperative Serum Levels of Periostin (PN) in Early Breast Cancer (BCa). <i>International Journal of Molecular Sciences</i> , 2015 , 16, 17181-92	6.3	22
155	Enterolactone in breast cyst fluid: correlation with EGF and breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2003 , 79, 17-23	4.4	22
154	The prognostic value of stromal and epithelial periostin expression in human breast cancer: correlation with clinical pathological features and mortality outcome. <i>BMC Cancer</i> , 2016 , 16, 95	4.8	21
153	Pemetrexed for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1545-58	4	21
152	Targeting androgen-independent pathways: new chances for patients with prostate cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 118, 42-53	7	21
151	Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2014 , 10, 79-90	3.6	21
150	Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial. <i>Cancer</i> , 1994 , 73, 1932-6	6.4	21
149	Role of blood groups as prognostic factors in primary breast cancer. <i>Oncology</i> , 1990 , 47, 308-12	3.6	21
148	Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 1990 , 116, 503-6	4.9	21

147	Safety of antiandrogen therapy for treating prostate cancer. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 1483-99	4.1	20
146	Hormone therapy of prostate cancer: is there a role for antiandrogen monotherapy?. <i>Critical Reviews in Oncology/Hematology</i> , 2000 , 35, 121-32	7	20
145	Interleukin-2, Interferon- γ and Interleukin-2 plus Interferon- γ in Renal Cell Carcinoma. A Randomized Phase II Trial. <i>Tumori</i> , 1998 , 84, 534-539	1.7	20
144	Afatinib for the treatment of advanced non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 889-903	4	19
143	Prostate cancer: prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression. <i>International Journal of Oncology</i> , 2014 , 44, 1589-98	4.4	19
142	The application of atmospheric pressure matrix-assisted laser desorption/ionization to the analysis of long-term cryopreserved serum peptidome. <i>Analytical Biochemistry</i> , 2011 , 417, 174-81	3.1	19
141	Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial. <i>Oncology</i> , 2008 , 74, 223-8	3.6	19
140	EGF in breast cyst fluid: relationships with intracystic androgens, estradiol and progesterone. <i>International Journal of Cancer</i> , 1991 , 47, 523-6	7.5	19
139	Complement C3f serum levels may predict breast cancer risk in women with gross cystic disease of the breast. <i>Journal of Proteomics</i> , 2013 , 85, 44-52	3.9	18
138	Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy. <i>Lung Cancer</i> , 2013 , 81, 236-40	5.9	18
137	Oral vinorelbine in the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1585-99	4	18
136	Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1989 , 12, 43-5	2.7	18
135	Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 775-84	4.4	17
134	Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-alpha. <i>Journal of Cancer Research and Clinical Oncology</i> , 1995 , 121, 753-6	4.9	17
133	Activity of 4-HPR in superficial bladder cancer using DNA flow cytometry as an intermediate endpoint. <i>Journal of Cellular Biochemistry</i> , 1992 , 161, 139-47	4.7	17
132	Risk of new primaries after chemotherapy and/or tamoxifen treatment for early breast cancer. <i>Annals of Oncology</i> , 1996 , 7, 239-44	10.3	16
131	Nonimmune idiopathic hydrops fetalis and congenital lymphatic dysplasia. <i>American Journal of Medical Genetics, Part A</i> , 2006 , 140, 678-84	2.5	16
130	Nuclear matrix proteins changes in cancerous prostate tissues and their prognostic value in clinically localized prostate cancer. <i>Prostate</i> , 2003 , 55, 259-64	4.2	16

129	Phase II study of navelbine in advanced renal cell carcinoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 804-5		16
128	Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review. <i>Clinical Medicine Insights Reproductive Health</i> , 2019 , 13, 1179558119864384	6.5	15
127	Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer. <i>Cell Communication and Signaling</i> , 2017 , 15, 51	7.5	15
126	Immunohistochemistry in non-immune hydrops fetalis: a single center experience in 79 fetuses. <i>American Journal of Medical Genetics, Part A</i> , 2010 , 152A, 1189-96	2.5	14
125	Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997 , 123, 407-10	4.9	14
124	Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 43, 461-6	3.5	14
123	Fertility, sexuality and cancer in young adult women. <i>Current Opinion in Oncology</i> , 2019 , 31, 259-267	4.2	14
122	Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients. <i>Cancers</i> , 2019 , 11,	6.6	13
121	Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery. <i>International Journal of Cancer</i> , 2015 , 137, 2394-402	7.5	13
120	Differential proteomic analysis of nuclear matrix in muscle-invasive bladder cancer: potential to improve diagnosis and prognosis. <i>Analytical Cellular Pathology</i> , 2008 , 30, 13-26	3.4	13
119	Prognostic value of cell cycle regulatory proteins in muscle-infiltrating bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006 , 132, 757-64	4.9	13
118	Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.C.A.P.) study. <i>Prostate</i> , 1987 , 11, 243-55	4.2	13
117	Esophageal Involvement in Breast Cancer. Report of Six Cases. <i>Tumori</i> , 1982 , 68, 149-153	1.7	13
116	Predictors of long-term response to abiraterone in patients with metastatic castration-resistant prostate cancer: a retrospective cohort study. <i>Oncotarget</i> , 2016 , 7, 40085-40094	3.3	13
115	Lymphoscintigraphic evaluation of congenital lymphedema of the newborn. <i>Clinical Nuclear Medicine</i> , 2002 , 27, 383-4	1.7	13
114	A hnRNP K?AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	12
113	Use of metronomic chemotherapy in oncology: Results from a national Italian survey. <i>Tumori</i> , 2011 , 97, 454-458	1.7	12
112	Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer. <i>Oncology</i> , 2010 , 78, 274-81	3.6	12

111	Comparison of an LH-RH analogue (Goserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group. <i>European Urology</i> , 2000 , 37, 205-11	10.2	12
110	Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758834017745819	5.4	11
109	Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015 , 10, e50-2	8.9	11
108	Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer. <i>Future Oncology</i> , 2013 , 9, 1375-88	3.6	11
107	Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. <i>Prostate</i> , 2011 , 71, 1466-79	4.2	11
106	Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study. <i>Oncology</i> , 1997 , 54, 102-7	3.6	11
105	Adjuvant chemotherapy of bladder cancer. <i>Annals of Oncology</i> , 2006 , 17 Suppl 5, v129-32	10.3	11
104	Evidence for testicular impairment after long-term treatment with a luteinizing hormone-releasing hormone agonist in elderly men. <i>Journal of Urology</i> , 1989 , 142, 1235-8	2.5	11
103	Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5023-5023	2.2	11
102	Opinions concerning euthanasia, life-sustaining treatment and acceleration of death: results of an Italian Association of Medical Oncology (AIOM) survey. <i>Annals of Oncology</i> , 2008 , 19, 1947-54	10.3	10
101	Switching to aromatase inhibitors in early breast cancer. <i>Lancet, The</i> , 2007 , 369, 533-5	40	10
100	Leiomyosarcoma of the broad ligament: a case report and review of literature. <i>International Journal of Gynecological Cancer</i> , 2005 , 15, 1226-9	3.5	10
99	Epidermal growth factor in breast cyst fluids. Relationships with the morphology of cyst epithelium. <i>Annals of the New York Academy of Sciences</i> , 1990 , 586, 137-42	6.5	10
98	Management of young women with early breast cancer. <i>ESMO Open</i> , 2018 , 3, e000458	6	10
97	Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2015 , 193, 1905-10	2.5	9
96	The Medical Oncologist's Role in Palliative Care: AIOM's Position. <i>Tumori</i> , 2009 , 95, 652-654	1.7	9
95	Epidemiology of Kidney Cancer. <i>European Urology Supplements</i> , 2006 , 5, 558-565	0.9	9
94	Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer. <i>Clinical Breast Cancer</i> , 2004 , 5 Suppl 1, S13-7	3	9

93	Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2005 , 56, 415-20	3.5	9
92	Chemotherapy with or without tamoxifen in postmenopausal patients with late breast cancer. A randomized study. <i>The Journal of Steroid Biochemistry</i> , 1985 , 23, 1123-7		9
91	FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. <i>Scandinavian Journal of Urology</i> , 2018 , 52, 349-357	1.6	9
90	Nuclear matrix protein expression in prostate cancer: possible prognostic and diagnostic applications. <i>Anticancer Research</i> , 2005 , 25, 3999-4004	2.3	9
89	Belagenpumatucel-L for the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 1371-9	5.4	8
88	Atezolizumab and bladder cancer: facing a complex disease. <i>Lancet, The</i> , 2018 , 391, 305-306	4.0	8
87	Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast. <i>International Journal of Cancer</i> , 2001 , 95, 260-5	7.5	8
86	Management of breast cancer: is there a role for somatostatin and its analogs?. <i>Chemotherapy</i> , 2001 , 47 Suppl 2, 62-77	3.2	8
85	Presence and distribution of growth factors in breast cyst fluid. <i>Annals of the New York Academy of Sciences</i> , 1996 , 784, 542-9	6.5	8
84	Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer. <i>European Journal of Endocrinology</i> , 1993 , 129, 315-21	6.5	8
83	Fibronectin concentration in the plasma of patients with malignant and benign breast disease. <i>Cancer Letters</i> , 1986 , 33, 317-23	9.9	8
82	Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2016 , 16, 1142-54	2.2	8
81	Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 1007-17	5.4	7
80	Prognostic value of nuclear matrix protein expression in localized prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012 , 138, 1379-84	4.9	7
79	Epidermal growth factor content of breast cyst fluids from women with breast cancer or proliferative disease of the breast. <i>Breast Cancer Research and Treatment</i> , 1995 , 33, 219-24	4.4	7
78	Endocrine therapy of breast cancer. The experience of the Italian Cooperative Group for Chemohormonal Therapy of Early Breast Cancer (GROCTA). <i>Annals of the New York Academy of Sciences</i> , 1993 , 698, 318-29	6.5	7
77	Genitourinary tumours in the targeted therapies era: new advances in clinical practice and future perspectives. <i>Anti-Cancer Drugs</i> , 2016 , 27, 917-43	2.4	7
76	Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients. Very late results of the 'gruppo di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)' 01-Trial in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 453-61	4.4	6

75	Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era. <i>International Journal of Hematology</i> , 2010 , 91, 342-4; author reply 345-6	2.3	6
74	Differential expression of nuclear lamins in normal and cancerous prostate tissues. <i>Oncology Reports</i> , 2006 , 15, 609	3.5	6
73	Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretion. <i>Prostate</i> , 1994 , 24, 17-23	4.2	6
72	Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Italian Prostatic Cancer Project (PONCAP). <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 1100-4		6
71	Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer. <i>Cancers</i> , 2020 , 12,	6.6	6
70	Androgen-Deprivation Therapy Is More Than Palliation in Oligometastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2350	2.2	6
69	Treatment of elderly patients with metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 323-34	3.5	5
68	Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 76-7		5
67	Medical treatment of advanced renal cell carcinoma: present options and future directions. <i>Cancer Treatment Reviews</i> , 1996 , 22, 85-104	14.4	5
66	Combination Chemotherapy with Vinblastine, Bleomycin and Methotrexate in Dtic-resistant Metastatic Melanoma. <i>Tumori</i> , 1979 , 65, 237-240	1.7	5
65	Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!. <i>European Urology</i> , 2018 , 73, 147-148	10.2	5
64	Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e1257-e1265	3.3	5
63	A Case of Advanced Mucinous Adenocarcinoma of Bladder in an Adult Patient Treated With Capecitabine-Based Chemotherapy and Review of Literature. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e365-8	3.3	4
62	Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study. <i>British Journal of Cancer</i> , 2020 , 122, 1611-1617	8.7	4
61	Incidental advanced-stage Hodgkin lymphoma diagnosed at the time of radical prostatectomy for prostatic cancer: a case report and review of literature. <i>BMC Cancer</i> , 2014 , 14, 613	4.8	4
60	Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study. <i>Annals of Oncology</i> , 1997 , 8, 745-50	10.3	4
59	Lack of effectiveness of adjuvant alternating chemotherapy in node-positive, estrogen-receptor-negative premenopausal breast cancer patients: results of a multicentric Italian study. The Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group (GROCTA). <i>Cancer Investigation</i> , 1997 , 15, 505-12	2.1	4
58	Endothelial cells increase the radiosensitivity of oropharyngeal squamous carcinoma cells in collagen gel. <i>Oral Oncology</i> , 2004 , 40, 214-22	4.4	4

57	Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. <i>Oncology</i> , 1996 , 53, 349-53	3.6	4
56	Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 529-529	2.2	4
55	Immunotherapy for genitourinary cancer: state of the art and new perspectives. <i>Anti-Cancer Drugs</i> , 2016 , 27, 585-99	2.4	4
54	To switch or not to switch? A real-life experience using dexamethasone in combination with abiraterone. <i>Therapeutic Advances in Urology</i> , 2019 , 11, 1756287219854908	3.2	3
53	Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e724-e732	3.3	3
52	The MAINSAIL trial: an expected failure. <i>Lancet Oncology</i> , 2015 , 16, 355-6	21.7	3
51	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. <i>European Journal of Cancer</i> , 2020 , 136, 43-51	7.5	3
50	Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies. <i>Oncology</i> , 2001 , 60, 116-22	3.6	3
49	Intravesical idarubicin: a dose-finding study. <i>Cancer Chemotherapy and Pharmacology</i> , 1996 , 38, 102-5	3.5	3
48	Somatuline and tamoxifen in postmenopausal breast cancer patients. <i>Annals of the New York Academy of Sciences</i> , 1993 , 698, 362-6	6.5	3
47	Presence of immunoassayable transforming growth factor-beta 1 (TGF-beta 1) in breast cyst fluid (BCF): relationship with the intracystic electrolyte and epidermal-growth-factor (EGF) content. <i>International Journal of Cancer</i> , 1994 , 59, 725-7	7.5	3
46	Phase II Study with Lonidamine in the Treatment of Hormone-Refractory Prostatic Cancer Patients. <i>Tumori</i> , 1992 , 78, 137-139	1.7	3
45	Nafarelin acetate and benign prostatic hyperplasia. <i>New England Journal of Medicine</i> , 1988 , 318, 580-1	59.2	3
44	Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone (CbzP) in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 253-253	2.2	3
43	Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients. <i>International Journal of Biological Markers</i> , 2006 , 21, 123-6	2.8	3
42	Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study. <i>Cancer Treatment and Research Communications</i> , 2020 , 25, 100221	2	3
41	Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer. <i>Translational Oncology</i> , 2020 , 13, 100789	4.9	2
40	Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case report. <i>Tumori</i> , 2015 , 101, e79-81	1.7	2

39	Recurrent intestinal perforation associated with thrombosis of inferior vena cava: uncommon presentation of antiphospholipid syndrome. <i>Journal of Rheumatology</i> , 2008 , 35, 2291-2	4.1	2
38	Ifosfamide in urologic cancer. <i>Oncology</i> , 2003 , 65 Suppl 2, 67-72	3.6	2
37	Effects of three cytokine regimens on hematologic recovery and progenitor cell mobilization after high-dose cyclophosphamide, etoposide, and cisplatin. <i>Oncology</i> , 2000 , 59, 7-13	3.6	2
36	Is the use of anti-androgen monotherapy appropriate in patients with advanced prostate cancer?. <i>Journal of Clinical Oncology</i> , 2000 , 18, 448-50	2.2	2
35	Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes: 5-year results of a pilot trial. <i>Oncology</i> , 2001 , 60, 221-7	3.6	2
34	Megestrol acetate plus alpha 2a interferon as second line therapy for postmenopausal patients with advanced breast cancer: results of a multicentric phase II trial. <i>Breast Cancer Research and Treatment</i> , 1995 , 33, 265-8	4.4	2
33	Alternating tamoxifen and medroxyprogesterone acetate in postmenopausal advanced breast cancer patients--short and long term endocrine effects. <i>Breast Cancer Research and Treatment</i> , 1987 , 10, 201-4	4.4	2
32	Single skull metastasis 15 years after primary treatment of prostate cancer and with undetectable PSA levels: a case report and review of the literature. <i>Tumori</i> , 2013 , 99, e220-4	1.7	2
31	Reduced dose of cabazitaxel in metastatic castration-resistant prostate cancer: from PROSELICA trial to the real life: A single institution experience. <i>Anti-Cancer Drugs</i> , 2019 , 30, 854-858	2.4	2
30	Dihydrotestosterone and bicalutamide do not affect periostin expression in androgen-dependent LNCaP prostate cancer cell lines. <i>Anticancer Research</i> , 2013 , 33, 815-20	2.3	2
29	Afatinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 1357-1364	3.6	1
28	Gynaecomastia: the anastrozole paradox. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2010 , 23, 205-6	1.6	1
27	Medical Treatment of Advanced Renal Cell Carcinoma: Present Options and Future Directions. <i>European Urology Supplements</i> , 2006 , 5, 619-626	0.9	1
26	Impact of Concurrent Radiotherapy on Chemotherapy Total Dose and Dose Intensity in Patients with Early Breast Cancer. <i>Tumori</i> , 2005 , 91, 126-130	1.7	1
25	Paclitaxel plus organoplatins: still the gold standard in advanced ovarian cancer?. <i>Annals of Oncology</i> , 2001 , 12, 1023-4	10.3	1
24	Priming action on progesterone receptor synthesis by estradiol and tamoxifen in the 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinoma. <i>Oncology</i> , 1987 , 44, 248-52	3.6	1
23	Hormone receptors in breast cancer: a conservative determination of receptors' presence in tumor tissue and ipsilateral normal mammary gland. <i>Journal of Surgical Oncology</i> , 1988 , 37, 89-93	2.8	1
22	Fibronectin Concentration in Plasma of Patients with Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 1986 , 464, 454-456	6.5	1

21	D-Trp-6-LH-RH treatment of advanced prostatic cancer. <i>Lancet, The</i> , 1986 , 1, 621	4.0	1
20	Italian national consensus conference on prostate cancer screening (Florence, May 17, 2003)--final consensus document. <i>International Journal of Biological Markers</i> , 2003 , 18, 238-40	2.8	1
19	Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5529-5529	2.2	1
18	Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 431-431 ²	2.2	1
17	A Case of Plasmacytoid Variant of Bladder Cancer With a Single Penile Metastasis and a Complete Response to Carboplatin-Based Chemotherapy and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e139-42	3.3	1
16	Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 3679-3692	7.4	1
15	Cell-free methylated DNA (cfMeDNA) immunoprecipitation and high throughput sequencing technology (cfMeDIP-seq) in patients with clear cell renal cell carcinoma (ccRCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3052-3052	2.2	0
14	Congenital Chylothorax of the Newborn.. <i>Respiration</i> , 2022 , 1-2	3.7	0
13	May Adjuvant Therapy Play A Role for the Management of Renal Cell Carcinoma? A Review of Literature and Ongoing Trials. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017 , 17, 1633-1643	2.2	
12	Re: J. Alfred Witjes. A case of abiraterone acetate withdrawal. <i>Eur Urol</i> 2013;64:517-8. <i>European Urology</i> , 2014 , 65, e54-5	10.2	
11	Efficacy of motesanib diphosphate in non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1771-80	4	
10	Breast-cancer in the elderly - detection and treatment modalities in 341 women. <i>International Journal of Oncology</i> , 1994 , 5, 1399-403	1	
9	Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1988 , 22, 172-4	3.5	
8	Phenotypic Modulation of Sex Steroid Receptors in DMBA-Induced Mammary Carcinoma of the Rat by Estrogens and Tamoxifena. <i>Annals of the New York Academy of Sciences</i> , 1986 , 464, 506-508	6.5	
7	PAZopanib as first line in METastatic RCC patients: A Real-world Italian experience (PAMERIT study) Preliminary results.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 611-611	2.2	
6	Circulating cell-free methylated DNA (cfmeDNA) to predict postoperative recurrence in patients with muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 454-454	2.2	
5	Bone Metastases from Prostate Cancer: Hormonal Therapy 2017 , 105-120		
4	Combinations of Hormonal Therapy and Chemotherapy 2017 , 135-146		

- 3 Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP).. *Journal of Clinical Oncology*, **2013**, 31, 189-189 2.2
- 2 Urethral stricture and scrotal abscess: a rare case presentation of penile cancer and review of the literature. *Aging Male*, **2020**, 23, 991-994 2.1
- 1 Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.. *ESMO Open*, **2022**, 7, 100431 6